Chickpea (Cicer arietinum) and other plant-derived protease inhibitor concentrates inhibit breast and prostate cancer cell proliferation in vitro

Nutrition and Cancer

Volumn 64, Issue 5, 2012, Pages 741-748

  Magee, Pamela J ^a   Owusu Apenten, Richard ^a   McCann, Mark J ^b   Gill, Chris I ^a   Rowland, Ian R ^c  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b AGRESEARCH GRASSLANDS   (New Zealand)

^c UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN; PROTEASE INHIBITOR CONCENTRATE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; CHICKPEA; DRUG ISOLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LENTIL; MALE; MOLECULAR WEIGHT; MUNG BEAN; NONHUMAN; PEA; PHASEOLUS VULGARIS; PROSTATE CANCER; SOYBEAN;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHYMOTRYPSIN; CICER; DRUG DISCOVERY; FABACEAE; FEMALE; HUMANS; MALE; MOLECULAR WEIGHT; OSMOLAR CONCENTRATION; PEPTIDES; PLANT EXTRACTS; PLANT PROTEINS; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; SERINE PROTEINASE INHIBITORS;

CICER ARIETINUM; GLYCINE MAX; PHASEOLUS VULGARIS;

EID: 84863713551     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.688914     Document Type: Article

References (55)

1. Mathers JC: Pulses and carcinogenesis: Potential for the prevention of colon, breast and other cancers. Br J Nutr 88, S273-S279, 2002.
2. Schuurman AG, Goldbohm RA, Dorant E, and van den Brandt PA: Vegetable and fruit consumption and prostate cancer risk: A cohort study in the Netherlands. Cancer Epidemiol Biomarkers Prev 7, 673-380, 1998.
3. Dong JY and Qin LQ: Soy isoflavones consumption and risk of breast cancer incidence or recurrence: A meta-Analysis of prospective studies. Breast Cancer Res Treat 125, 315-323, 2011.
4. Jian L: Soy, isoflavones, and prostate cancer. Mol Nutr Food Res 53, 217-226, 2009.
5. Chen YW, Huang SC, Lin-Shiau SY, and Lin JK: Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation ofMCF7 breast cancer cells through accumulation ofMAP kinase phosphatase-1. Carcinogenesis 26, 1296-1306, 2005.
6. McCormick DL, Johnson WD, Bosland MC, Lubet RA, and Steele VE: Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Nutr Cancer 57, 184-193, 2007.
7. Kennedy AR: Chemopreventive agents: Protease inhibitors. Pharmacol Ther 78, 167-209, 1998.
8. Kennedy AR: The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 68, 1406S-1412S, 1998.
9. GrantG,Dorard PM, Buchan WC,Armour JC, and Putztai A: Consumption of diets containing raw soya beans (Glycine max), kidney beans (Phaseolus vulgaris), cowpeas (Vigna-Unguiculata) or lupin seeds (Lupinus-Agustifolious) by rats for up to 700 days-effects on body composition and organ weights. Br J Nutr 73, 17-29, 1995.
10. Friedman M and Brandon DL: Nutritional and health benefits of soy proteins. J Agric Food Chem 49, 1069-1089, 2001.
11. Zhang LL, Wan XS, Donahue JJ, Ware JH, and Kennedy AR: Effects of the Bowman-Birk inhibitor on cologenic survival and cisplatin or radiation induced cytotoxicity in human breast, cervical and head and neck cancer cells. Nutr Cancer 33, 165-173, 1999.
12. Troll W and Weisner R: Protease inhibitors: Possible anti-carcinogens in edible seeds. Prostate 4, 345-349, 1983.
13. KennedyARandWan XS: Effects of the Bowman-Birk inhibitor on growth, invasion and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 50, 125-133, 2002.
14. Tang M, Asamoto M, Ogawa K, Naiki-Ito A, Sato S, et al.: Induction of apoptosis in the LNCaP human prostate carcinoma cell line and prostate adenocarcinomas of SV40T antigen transgenic rats by the Bowman-Birk inhibitor. Pathol Int 59, 790-796, 2009.
15. Kennedy AR,Billings PC,Wan XS, andNewberne PM: Effects of Bowman-Birk inhibitor on rat colon carcinogenesis. Nutr Cancer 43, 174-186, 2002.
16. Kennedy AR, Beazer-Barclay Y, Kinzler KW and Newberne PM: Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res 56, 679-682, 1996.
17. Kennedy AR, Szuhaj BF, Newberne PM, and Billings PC: Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 19, 281-302, 1993.
18. Malkowicz SB, McKenna WG, Vaughn DJ,Wan XS, Propert KJ, et al.: Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate 48, 16-28, 2001.
19. Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, et al.: Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6, 4684-4691, 2000.
20. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, et al.: Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 9, 43-47, 2000.
21. Lichtenstein GR,Deren JJ, Katz S, Lewis JD,Kennedy AR, et al.: Bowman-Birk inhibitor concentrate: A novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci 53, 175-180, 2008.
22. Yavelow J, Caggana M, and Beck KA: Proteases occurring in the cell membrane: A possible cell receptor for the Bowman-Birk type protease inhibitors. Cancer Res 47, 1598-1601, 1987.
23. Jin XL, Hirosaki T, Lin CY, Dickson RB, Higashi S, et al.: Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin. J Cell Biochem 95, 632-647, 2005.
24. Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, et al.: In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncology 27, 1061-1071, 2005.
25. Ware JH, Wan XS, Rubin H, Schechter NM, and Kennedy AR: Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344, 133-138, 1997.
26. Stephens RW, Brunner N, Janicke F, and Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 52, 99-111, 1998.
27. Rabbani SA: Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 12, 135-142, 1998.
28. Park JH, Jeong HJ, and De Lumen BO: Contents and bioactivities of lunasin, Bowman-Birk inhibitor, and isoflavones in soybean seed. J Agric Food Chem 53, 2686-7690, 2005.
29. De Lumen BO: Lunasin: A cancer-preventive soy peptide. Nutrition Rev 63, 16-21, 2005.
30. Frenkel K, Chrzan K, Ryan CA, Weisner R, and Troll W: Chymotrypsinspecific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes. Carcinogenesis 8, 1207-1212, 1987.
31. Tamir S, Bell J, Finlay TH, Sakal E, Smirnoff P, et al.: Isolation, characterization, and properties of a trypsin-chymotrypsin inhibitor from amaranth seeds. J Protein Chem 15, 219-229, 1996.
32. Fernandes AO and Banerji AP: Inhibition of benzopyrene-induced forestomach tumors by field bean protease inhibitor(s). Carcinogenesis 16, 1843-1846, 1995.
33. Clemente A, Gee JM, Johnson IT, Mackenzie DA, and Domoney C: Pea (Pisum sativum L) protease inhibitors from the Bowman-Birk class influence the growth of human colorectal adenocarcinoma HT29 cells in vitro. J Agric Food Chem 53, 8979-8986, 2005.
34. Joanitti GA, Azevedo RB, and Freitas SM: Apoptosis and lysosome membrane permeabilization induction on breast cancer cells by an anticarcinogenic Bowman-Birk protease inhibitor from Vigna unguiculata seeds. Cancer Lett 293, 73-81, 2010.
35. Kassell B: Trypsin and chymotrypsin inhibitors from soybeans. Methods Enzymol 19, 853-852, 1970.
36. Rafiq A and Bailey G: A more sensitive Hummel assay for chymotrypsin. Anal Biochem 257, 233-234, 1998.
37. Brewer JM, Robert CW, Stimson WH, and Alexander J: Accurate determination of adjuvant-Associated protein or peptide by Ninhydrin assay. Vaccine 13, 1441-1444, 1995.
38. Soule H, Vazquez J, Long A, Albert S, and Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51, 1409-1416, 1973.
39. Cailleau R, Young R, Olive M, and Reeves W: Breast tumour cell lines from pleural effusions. J Natl Cancer Inst 53, 661-674, 1974.
40. Horoszewicz J, Leong S, Kawinski E, Karr J, Rosenthal H et al. : LNCaP model of human prostatic carcinoma. Cancer Res 43, 1809-1818, 1983.
41. Kaighn M, Shankar N, Ohnuki Y, Lechner J, and Jones L: E stablishment and characterization of a human prostate carcinoma cell line (PC-3). Invest Urol 17, 16-23, 1979.
42. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Method 65, 55-63, 1983.
43. Baldwin EL and Osheroff N: E toposide, topoisomerase II and cancer. Curr Med Chem 5, 363-372, 2005.
44. Ho VSM and Ng TB: A Bowman-Birk trypsin inhibitor with antiproliferative activity from Hokkaido large black soybeans. J Pept Sc 14, 278-282, 2008.
45. Hsieh CC, Hernandez-Ledesma B, Jeong HJ, Park JH, and De Lumen BO: Complementary roles in cancer prevention: Protease inhibitor makes the cancer preventive peptide lunasin bioavailable. PLoS One 5(1), e8890, 2010. doi: 10.1371/journal.pone.0008890.
46. Yavelow J, Collins M, Birk Y, Troll W and Kennedy AR: Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-rayinduced transformation in vitro. Proc Natl Acad Sci 82, 5395-5399, 1985.
47. Giron-Calle J, Vioque J, delMar Yust M, Pedroche J, Alaiz M, et al.: E ffect of chickpea aqueous extracts, organic extracts and protein concentrates on cell proliferation. J Med Food 7, 122-129, 2004.
48. Kennedy AR: Prevention of carcinogenesis by protease inhibitors. Cancer Res 54, 1999S-2005S, 1994.
49. Chang JD, Li JH, Billings PC, and Kennedy AR: Effects of protease inhibitors on c-myc expression in normal and transformed C3H 10T1/2 cell lines. Mol Carcinog 3, 226-232, 1990.
50. Caggana M and Kennedy AR: C-fos mRNA levels are reduced in the presence of antipain and Bowman-Birk inhibitor. Carcinogenesis 10, 2145-2148, 1989.
51. Voorhees PM, Dees EC, O'Neil B, and Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res 9, 6316-6325, 2003.
52. Lam Y, Galvez A, and De Lumen BO: Lunasin suppresses E1A-mediated transformation of mammalian cells but does not inhibit growth of immortalized and established cancer cell lines. Nutr Cancer 47, 88-94, 2003.
53. Galvez AF, Chen N, Macasieb J, and De Lumen BO: Chemopreventive property of a soybean peptide (lunasin) that binds to deacetylated histones and inhibits acetylation. Cancer Res 61, 7473-7478, 2001.
54. Jeong HJ, Lam Y, and De Lumen BO: Barley lunasin suppresses ras-induced colony formation and inhibits core histone acetylation in mammalian cells. J Agric Food Chem 50, 5903-5908, 2002.
55. St Clair W, Billings P, Carew J, Keller-McGandy C, Newberne P, et al.: Suppression of DMH-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res 50, 580-586, 1990.